Article info
PDFPatient safety and risk management
PS-072 Incidence, management and cost of Telaprevir/Boceprevir-Induced thrombocytopenia during the first 12 weeks of treatment in patients with hepatitis C
Citation
PS-072 Incidence, management and cost of Telaprevir/Boceprevir-Induced thrombocytopenia during the first 12 weeks of treatment in patients with hepatitis C
Publication history
- First published March 24, 2015.
Online issue publication
May 13, 2016
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions